Top in cardiology: Ventricular assist device battery recall; COVID-19-related myocarditis
Click Here to Manage Email Alerts
A recall of Medtronic’s Heartware ventricular assist device batteries has been designated as class I — the most serious type.
According to the FDA, the device batteries may experience electrical faults and cause the system to unexpectedly fail. The manufacturer reported receiving 1,159 complaints, six injuries and one death attributable to this issue. It was the top story in cardiology last week.
Another top story was on the risk for myocarditis after SARS-CoV-2 infection vs. vaccination. While the overall risk was small, researchers reported that it was significantly higher after infection among unvaccinated individuals compared with after COVID-19 vaccination.
Read these and more top stories in cardiology below:
FDA designates recall of HVAD batteries as class I
The FDA has designated Medtronic’s recall of its ventricular assist device batteries due to electrical faults causing battery failure as class I, the most serious type. Read more.
Myocarditis risk ‘significantly higher’ with COVID-19 vs. vaccination
Data from a large cohort in England suggest that risk for myocarditis, while small overall, is significantly higher after SARS-CoV-2 infection in unvaccinated individuals vs. after COVID-19 vaccination, researchers reported. Read more.
No association between messenger RNA-based COVID-19 vaccines and MI, pulmonary embolism
A database analysis showed no association between messenger RNA COVID-19 vaccines and risk for acute MI, stroke or pulmonary embolism, but a slight increase in risk for pulmonary embolism and myocardial infarction after receiving the AstraZeneca or Janssen vaccines. Read more.
TIME: Evening dosing of BP medication ‘no better or worse’ than morning dosing
Patients taking antihypertensive medication in the evening experienced no difference in myocardial infarction, stroke or cardiovascular death occurrence compared with patients taking them in the morning, a speaker reported. Read more.
Polypill soon after heart attack lowers risk for major adverse CV events: SECURE
In older adults, a polypill containing aspirin, an ACE inhibitor and a statin within 6 months after myocardial infarction lowered the risk for major adverse cardiovascular events compared with usual care, according to results of the SECURE trial. Read more.